Skip to Main content Skip to Navigation
Journal articles

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Abstract : PURPOSE: We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer. PATIENTS AND METHODS: We used data from the French E3N cohort study, with 80,391 postmenopausal women followed for a mean duration of 8.1 years; 2,265 histologically confirmed invasive breast cancers were identified through biennial self-administered questionnaires completed from 1990 to 2002. The relative risks (RRs) were estimated using Cox proportional hazards models. RESULTS: Compared with postmenopausal hormone therapy (HT) never-use, ever-use of estrogen+progesterone was not significantly associated with the risk of any breast cancer subtype, but increasing duration of estrogen+progesterone was associated with increasing risks of lobular (P = .06) and estrogen receptor-positive/progesterone receptor-negative (ER+/PR-; P = .02). Estrogen+dydrogesterone was associated with a significant increase in risk of lobular carcinoma (RR, 1.7; 95% CI, 1.1 to 2.6). Estrogen+other progestagens was associated with significant increases in risk of ductal and lobular carcinomas (RR, 1.6; 95% CI, 1.3 to 1.8; and 2.0; 95% CI, 1.5 to 2.7, respectively), of ER+/PR+ and ER+/PR- carcinomas (RR, 1.8; 95% CI, 1.5 to 2.1; and 2.6; 95% CI, 1.9 to 3.5, respectively), but not of ER-/PR+ or ER-/PR- carcinomas (RR, 1.0; 95% CI, 0.5 to 2.1; and 1.4; 95% CI, 0.9 to 2.0, respectively). CONCLUSION: The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR-, and to affect both ductal and lobular carcinomas.
Complete list of metadatas

Cited literature [67 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00271114
Contributor : F. Clavel-Chapelon <>
Submitted on : Tuesday, April 8, 2008 - 11:42:06 AM
Last modification on : Wednesday, September 16, 2020 - 5:04:40 PM
Long-term archiving on: : Thursday, May 20, 2010 - 11:04:40 PM

Identifiers

Collections

Citation

Agnès Fournier, Alban Fabre, Sylvie Mesrine, Marie-Christine Boutron-Ruault, Franco Berrino, et al.. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2008, 26 (8), pp.1260-8. ⟨10.1200/JCO.2007.13.4338⟩. ⟨inserm-00271114⟩

Share

Metrics

Record views

603

Files downloads

1348